Evidence map›Paper›PMID 25684269›Full record

ReviewProteomics2015

Unlocking proteomic heterogeneity in complex diseases through visual analytics.

Suresh K Bhavnani, Bryant Dang, Gowtham Bellala, Rohit Divekar, Shyam Visweswaran, Allan R Brasier, Alex Kurosky

Abstract readReview
In one paragraph

Review in Proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Subtyping Social Determinants of Health inmedRxiv : the preprint server for health sciences · 2023
    Article
  4. Article
  5. Review
  6. Enabling Comprehension of Patient Subgroups and Characteristics in Large Bipartite Networks: Implications for Precision Medicine.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Suresh K BhavnaniInstitute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Molecular Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Bryant Dang
Gowtham Bellala
Rohit Divekar
Shyam Visweswaran
Allan R Brasier
Alex Kurosky
The University of Texas Medical Branch at Galveston · USHewlett-Packard (United States) · USMayo Clinic in Florida · USUniversity of Pittsburgh · US

Funding

UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
UTMB Clinical and Translational Science AwardKL2TR000072 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$422k
Novel Systems for Rapidly Identifying toxic Chemicals During EmergenciesR21OH009441 · OH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BHAVNANI, SURESH KHUSHI · 2010 to 2011
$416k
NCATS NIH HHS 1UL1TR000071NCATS NIH HHS KL2 TR000072NCATS NIH HHS UL1 TR000071NHLBI NIH HHS HHSN268201000037CNIOSH CDC HHS R21 OH009441NIOSH CDC HHS R21OH009441-01A2PHS HHS HHSN268201000037C-0-0-1
6 · The paper itself

Abstract

Despite years of preclinical development, biological interventions designed to treat complex diseases such as asthma often fail in phase III clinical trials. These failures suggest that current methods to analyze biomedical data might be missing critical aspects of biological complexity such as the assumption that cases and controls come from homogeneous distributions. Here we discuss why and how methods from the rapidly evolving field of visual analytics can help translational teams (consisting of biologists, clinicians, and bioinformaticians) to address the challenge of modeling and inferring heterogeneity in the proteomic and phenotypic profiles of patients with complex diseases. Because a primary goal of visual analytics is to amplify the cognitive capacities of humans for detecting patterns in complex data, we begin with an overview of the cognitive foundations for the field of visual analytics. Next, we organize the primary ways in which a specific form of visual analytics called networks has been used to model and infer biological mechanisms, which help to identify the properties of networks that are particularly useful for the discovery and analysis of proteomic heterogeneity in complex diseases. We describe one such approach called subject-protein networks, and demonstrate its application on two proteomic datasets. This demonstration provides insights to help translational teams overcome theoretical, practical, and pedagogical hurdles for the widespread use of subject-protein networks for analyzing molecular heterogeneities, with the translational goal of designing biomarker-based clinical trials, and accelerating the development of personalized approaches to medicine.

Indexed as

Data Interpretation, StatisticalBoutonneuse FeverComputer GraphicsGene Regulatory NetworksHumansProtein Interaction MapsProteomeProteomicsProteomeBioinformaticsMolecular and clinical profilesNetwork analysisPersonalized medicineProteomic heterogeneitySubject-Protein Networks

Identifiers

PMID25684269
PMCPMC4471338
OpenAlexW1974049789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.